glp-1 agonists diabetes GLP-1R and Upcoming wave of hormone-based therapies

Additionally, the study found that resmetirom was safe and well-tolerated, with no significant difference in the primary endpoint of incidence of treatment-emergent adverse events between the groups

11beta-hydroxysteroid dehydrogenases: intracellular gate-keepers of tissue glucocorticoid action

However, its mechanism of action is linked to reduced bone formation and reduced osteoclast surfaces

GLP-1R Agonist Use in Clinical Practice In both Europe and the United States, GLP-1R agonists are approved for a range of metabolic and cardiovascular conditions

Witkiewitz, K

Of note, a small number of cases of acute pancreatitis associated with GLP-1RA use have been reported in clinical trials: 38 cases in 17,775 patient-years of exposure compared with 9 events in 5863 patient-years of exposure with the comparator treatment